Scalper1 News
Biotechs Kite Pharma (KITE) and Bluebird Bio (BLUE) announced Monday that they’re collaborating on a new treatment for human papillomavirus (HPV), sending both stocks rising. The two companies plan to combine Kite’s expertise with T cell receptors (TCRs), components of cells that regulate the immune response, with Bluebird’s capabilities in gene editing and lentiviruses (harmless viruses that deliver gene therapies). They’re targeting HPV type 16, Scalper1 News
Scalper1 News